Merozan

Meropenem, the active ingredient in Merozan, is a carbapenem antibiotic presented as an injection solution for intravenous use. It is indicated for the treatment of severe bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, ventilator‑associated pneumonia and septicemia in hospitalized adult patients. The drug is administered under strict aseptic conditions in clinical settings.

GNH USA supplies Merozan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections.

Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure. Complicated urinary tract infections: clears infection and prevents progression. Hospital‑acquired pneumonia: resolves pulmonary infection and improves respiratory function. Ventilator‑associated pneumonia: eliminates causative pathogens and supports weaning. Septicemia: rapidly reduces bacteremia and stabilizes hemodynamics.

Adverse reactions to meropenem may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Nausea: transient feeling of sickness. - Diarrhea: loose stools, often self‑limiting. - Elevated liver enzymes: mild, reversible increase in transaminases. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of respiratory distress, hypotension, and rash. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption. - Seizures: especially in patients with renal impairment or high doses. - Thrombocytopenia: marked reduction in platelet count. - Renal toxicity: acute kidney injury in predisposed patients. - Stevens‑Johnson syndrome: rare severe skin reaction.

When using meropenem, clinicians should consider several precautionary measures to ensure safe administration.

Renal function assessment: dose adjustment may be required in patients with impaired clearance. Hypersensitivity screening: avoid use in individuals with known β‑lactam allergy. Monitoring for seizures: observe neurological status, especially in renal failure or high doses. Liver function tests: check baseline and periodic transaminases during therapy. Concomitant nephrotoxic drugs: use caution when combined with other renal‑impacting agents. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concurrent use may reduce serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxicity potential; monitor renal function. - Loop diuretics: may enhance ototoxicity when used with aminoglycosides and meropenem. - Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters. - Oral contraceptives: theoretical reduction in efficacy; advise additional contraceptive measures.